Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients
- 1 March 1994
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 55 (3) , 179-185
- https://doi.org/10.1002/jso.2930550310
Abstract
Lymphokine-activated killer (LAK) cell activity of peripheral blood mononuclear cells (PBM), spleen cells (SPC), regional lymph node cells (LNC), and tumor-infiltrating lymphocytes (TIL), induced by activation with interleukin 2 (IL 2) for 4 days, was evaluated in patients with gastric carcinoma. TIL exhibited the lowest LAK activity and the cytotoxicity of LNC was significantly lower than that of either PBM or SPC. There was no difference between PBM and SPC. Then, there were significant correlations of LAK activity among PBM, SPC, and LNC, whereas poor correlations were observed in the cytotoxicity between TIL and PBM, SPC, or LNC. Phenotypic analysis of each cell population was performed before and after activation with IL 2. Before culture, the cells mediating natural killer (NK) activity such as CD16+, CD56+, and CD57+ cells were few in LNC and TIL. However, CD56+ and CD57+ cells in TIL were increased after culture. Then, CD4+Leu8+ and CD8+CD11+ cells, which identify suppressor cell function, were not elevated in LNC or TIL, as compared to that in PBM or SPC. Further, the proportions of OKIa1+ and CD25+ cells expressing T-cell activation and IL 2 receptor were uniformly increased in all cell populations after culture. These results indicate the differential reactivity of each lymphocyte population to IL 2 and fundamental dysfunction of LNC and, especially TIL, suggesting the specific influence of the local tumor environment on the lymphocyte function in the area in patients with gastric carcinoma.Keywords
This publication has 16 references indexed in Scilit:
- Functional characterization of tumor‐infiltrating lymphocytes, lymph‐node lymphocytes and peripheral‐blood lymphocytes from patients with breast cancerInternational Journal of Cancer, 1991
- Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: Cytotoxicity, growth kinetics and phenotypeCancer Immunology, Immunotherapy, 1990
- Lymphokine‐activated killer‐cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancerInternational Journal of Cancer, 1989
- Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancerEuropean Journal of Cancer and Clinical Oncology, 1989
- Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleenImmunology Today, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytesBiochemical and Biophysical Research Communications, 1982
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Prostaglandin inhibition of T-cell proliferation is mediated at two levelsCellular Immunology, 1981
- Suppressor cell activity of lymphocytes infiltrating human lung and breast tumoursInternational Journal of Cancer, 1979